#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Risks of long-term bisphosphonate treatment


Authors: O. Růžičková
Authors place of work: Revmatologický ústav Praha
Published in the journal: Čes. Revmatol., 29, 2021, No. 1, p. 41-48.
Category:

Summary

Postmenopausal osteoporosis is a chronic, metabolic skeletal disease characterized by low peak bone mass and rapid progressive bone loss associated with estrogen deficiency and aging. Osteoporosis affects a huge number of people, affects both sexes of all races, and its prevalence will continue to rise as the global population ages, making it a global health problem. Fractures then represent a logical consequence of osteoporosis, which entails considerable economic costs for society, healthcare providers, patients, and their families.

Recommendations for the treatment of osteoporosis usually provide general recommendations, however, not targeted, individual scenarios for long-term treatment. Anti-resorptive drugs, such as aminobisphosphonates, are usually recommended as first-line therapies and have dominated the treatment of osteoporosis for the past 20 years.

Rare side effects of bisphosphonate therapy may include osteonecrosis (ON) of the jaw, atypical femoral fractures, carcinogenicity, and prolonged fracture healing

Keywords:

osteoporosis – antiresorptive drugs – aminobisphosphonates – osteonecrosis of the jaw – atypical femoral fractures – carcinogenicity – prolonged fracture healing


Zdroje

1. Cosman F, de Beur SJ, LeBoff MS, et al. Clinicians guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25: 2359–2381.

2. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther 2004; 26: 841–854.

3. Solomon DH, Patric AR, Schousboe L, et al. The potential economic benefits of improved postfracture care: a cost–effectiveness analysis of a fracture liaison service in the US health-care systém. J Bone Miner Res 2014; 29: 1667–1674.

4. Kanis JA, Svedbom A, Harvey N, et al. The osteoporosis treatment gap. J Bone Miner Res 2014; 29: 1926–1928.

5. Quaseem A, Forciea MA, Mc Lean, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017; 166: 818–839.

6. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res 2015; 30: 3–23.

7. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29: 1–23.

8. Shane E, Burr D, Ebeling PR, et al. Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267–2294.

9. McClung MR, Harris ST, Miller PD, et al. Bisphosphonate therapy of osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126(1): 13–20.

10. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016; 374(3): 254–262.

11. Mignot MA, Taisne N, Legroux I, et al. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int 2017; 28(12): 3431–3438.

12. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–789.

13. Meier RP, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172: 930–936.

14. Serrano AJ, Begona L, Anitua E, et al. Systematic review and metaanalysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol 2013; 29(12): 1005–1014.

15. Lee SH, Chang SS, Lee M, et al. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis. Osteoporos Int 2014; 23(3): 1131–1139.

16. Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanism of acrion of bisphosphonates. Bone 1999; 24: 73S–79S.

17. Fleisch H. Bisphosphonates: Mechanism of action. Endocr Rev 1998; 19: 80–100.

18. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effect on osteoklast ultrastructure. J Clin Invest 1991; 88: 2095–2105.

19. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478–1487.

20. Baron R, Ferrari S, Russell RG. Denosumab and Bisphosphonates: Different mechanism of action and effects. Bone 2011; 48: 677–692.

21. Russell RG, Watts NB, Ebetino FH, et al. Mechanism of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733–759.

22. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermitent therapy for osteoporosis. Clin Pharmacokinet 2005; 44: 551–570.

23. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoorosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 875–883.

24. Neele SJ, Evertz R, De Valk-De Roo, et al. Effect of 1 year od discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002; 30: 599–603.

25. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011; 22: 2951–2961.

26. Allen MR. Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 2007; 7: 358–360.

27. Lesclous P, Abi Najm S, Carrel JP, et al. Bisphosphonate–assciated osteonecrosis of the jaw: A key role of inflammation? Bone 2009; 45: 843–852.

28. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24: 561–574.

29. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893–2897.

30. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567–1575.

31. Sim Ie, Sanders KM, Borromeo Gl, et al. Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. J Clin Endocrinol Metab 2015; 100: 3887–3893.

32. Ng AC, Png MA, Mohan PC, et al. Atypical femoral fractures: Transverse morphology at lateral cortex is a critical feature. J Bone Miner Res 2014; 29: 639–643.

33. Koh JS, Goh SK, Png MA, et al. Distribution of atypical fractures and cortical stress lesions in the femur: Implications on pathophysiology. Singapore Med J 2011; 52: 77–80.

34. Nieves LW, Bilezikian JP, Lane JM, et al. Fragility fractures of the hip and femur: Incidence and patient characteristics. Osteoporos Int 2010; 21: 399–408.

35. Probyn L, Cheung AM, Lang C, et al. Bilateral atypical femoral fractures: How much symmetry is there on imaging? Skeletal Radiol 2015; 44: 1579–1584.

36. Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011; 48: 966–971.

37. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010; 47: 169–180.

38. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728–1737.

39. Gasser J, Ingold P, Rebmann A, et al. Inhibition of FPP-synthase in osteoblasts may explain the blunting of the bone anabolic response to PTH observed after chronic exposure of rats to bisphosphonates. Osteoporos Int 2006; 17: S68–69.

40. Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res 2009; 24: 1132–1134.

41. Singer FR. Bone quality in Pagets disease of bone. Curr Osteoporos Rep 2016; 14: 39–42.

42. Lo JC, Hui RL, Grimsrud CD et al. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 2016; 85: 142–147.

43. Lu Liquing, Lu Lifen, Zhang J, et al. Potential risks of rare serious adverse effects related to long-term use of bisphosphonates: An overview of systematic reviews. J Clin Pharm Ther 2020; 45: 45–51.

44. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115–1117.

45. Lee SH, Chang SS, Lee M, et al. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta–analysis. Osteoporos Int 2014; 25(3): 1131–1139.

46. Lee S, Yin RV, Hirpara H, et al. Increased risk for atypical fractures associated with bisphosphonate use. Fam Pract 2015; 32(3): 276–281.

47. Gedmintas L, Solomon DH, Kim SC, et al. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical ferur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; 28(8): 1729–1737.

48. Lu YJ, Liu H. Meta-analysis of the relationship between bisphosphonates and atypical femoral fractures. Chin J Clinicians 2013; 7(20): 102–104.

49. Lin T, Wang C, Cai XZ, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 2012; 66(4): 399–408.

50. Chen LX, Ning GZ, Zhou ZR, et al. The carcinogenity of alendronate in patients with osteoporosis: evidence from cohort studies. PlosOne 2015; 10(4): e0123080.

51. Molvik H, Khan WS. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int 2015; 26(4): 1251–1260.

52. Yue B, Ng A, Tang H, et al. Delayed healing of lower limb fractures with bisphosphonate therapy. Ann R Coll Surg Engl 2015; 97(5): 333–338.

53. Cosman F. Long term treatment strategies for postmenopausal osteoporosis. Curr Opin Rheumatol 2018; 30: 420–426.

54. Pinkerton JAV, Aguirre FS, Blake J, et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017; 24: 728–753.

55. Lello S, Capozzi A, Scambia G. The tissue-selective estrogen complex (bazedoxifene/conjugated estrogens) for the treatment of menopause. Int J Endocrinol 2017; 2017: 5064725.

56. Cummings SR, Cosman F, Lewiecki EM, et al. Goal directed treatment for osteoporosis: a progress report from the ASBMR-NOR Working Group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017; 32: 3–10.

57. Cosman F, Cauley JA, Eastell R, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 2014; 99: 4546–4554.

58. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report for a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31: 1910.

59. McClung MR. Cancel the denosumab holiday. Osteoporos Int 2016; 27: 1677–1682.

60. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017; 5: 513–523.

61. Black DM, Reidl IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomised second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015; 30: 934–944.

62. Ferrari S, Adachi JD, Loppuner K, et al. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 2015; 26: 2763–2771.

63. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105: 11–17.

64. McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 2017; 28: 1723.

65. Cummings SR, Ferrari S, Eastel R, et al. Vertebral fractures after discontinuation of denosumab: a post hock analysis of the randomised placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018; 33: 190–198.

66. Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 2016; 27: 1929–1930.

67. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, et al. Several spontaneus vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 2016; 27: 1923–1925.

68. Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe rebound–associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 2016; 102: 354–358.

69. Polyzos SA, Terpos E. Clinical vertebral fractures following denosumab discontinuation. Endocrine 2016; 54: 271.

70. Popp A, Zysset P, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab: from clinic and biomechanice. Osteoporos Int 2016; 27: 1917–1921.

71. Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound–associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017; 32: 1291–1296.

72. Roux C, Briot K. Imminent fracture risk. Osteoporos Int 2017; 28: 1765–1769.

73. van Geel TA, Huntjens KM, van den Bergh JP, et al. Timing of subsequent fracture after an initial fracture. Curr Osteoporos Rep 2010; 8: 118–122.

74. Kanis J. Characteristics of recurrent fractures. Osteoporos Int 2018; 29(8): 1747–1757.

75. Balasubramanian A. Risk of subsequent fractures after prior fracture among older women. Osteoporos Int 2019; 30(1): 79–92.

76. Gehlbach S, Saag KG, Adachi JD, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res 2012; 27: 645–653.

77. Cosman F, Krege JH, Looker AC, et al. Spine fracture prevalence in a nationally representative sample og US women and men aged over 40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013–2014. Osteoporos Int 2017; 28: 1857–1866.

78. Lewiecki EM, Binkley N, Morgan SL, et al. Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 2016; 19: 127–140.

79. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2016. Endocr Pract 2016; 22(Suppl 4): 1–42.

80. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756–765.

81. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–1822.

82. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomised extension to the HORIZON-Pivotal Fracture Triat (PFT). J Bone Miner Res 2012; 27: 243–244.

83. Cummings S, Vittinghoff E, Daizadeh N, et al. Virtual twin estimates: continued new vertebral and nonvertebral anti–fracture efficacy through 8 years of treatment with denosumab. Abstract. ASBMR; 2014; S114–S120.

84. Cosman F, Nieves JW, Dempster DW, et al. Treatment sequence matters: anabolic and antiresrptive therapy for osteo-porosis. J Bone Miner Res 2017; 32: 198–202.

85. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transition in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015; 386: 1147–1155.

86. Langdahl BL, Libanati C, Crittenden DB, et al. Romosotumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a Rndomised, open-label, phase 3 trial. Lancet 2017; 390: 1585–1594.

87. Brown JP. Antiresorptives: Safety concerns-clinical perspective. Toxicologic Pathology 2017; 45(7): 859–863.

88. Vang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 2011; 26: 553–560.

89. Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis: Expected benefits, potential harms, and drug holidays. Can Fam Physician 2014; 60: 324–333.

90. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update Executive Summary. Endocr Pract 2020; 26(5): 564–570.

91. Kanis JA, Cooper C, Rizzoli R, Reginster JY, et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 2019; 104: 235–238.

Štítky
Dermatology & STDs Paediatric rheumatology Rheumatology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#